iScienceGenetic & Genomic MedicinePeer-reviewed journal article
Common variants at 21q22.3 locus influence MX1 gene expression and susceptibility to severe COVID-19
Immacolata AndolfoiD, Roberta RussoiD, Vito Alessandro LasorsaiD, Sueva CantalupoiD, Barbara Eleni RosatoiD, Ferdinando BonfiglioiD, Giulia FrissoiD, Pasquale AbeteiD, Gian Marco Cassese, Giuseppe ServilloiD, Gabriella EspositoiD, Ivan GentileiD, Carmelo PiscopoiD, Romolo VillaniiD, Giuseppe FiorentinoiD, Pellegrino CerinoiD, Carlo BuonerbaiD, Biancamaria PierriiD, Massimo ZolloiD, Achille IolasconiD, Mario CapassoiD
Abstract
The COVID-19 disease, caused by the SARS-Cov-2, presents a heterogeneous clinical spectrum. The risk factors do not fully explain the wide spectrum of disease manifestations, so it is possible that genetic factors could account for novel insights into its pathogenesis. In our previous study, we hypothesized that common variants on chromosome 21, near TMPRSS2 and MX1 genes, may be genetic risk factors associated to the different clinical manifestations of COVID-19. Here, we performed an in-depth genetic analysis of chromosome 21 exploiting the genome-wide association study data including 6,406 individuals hospitalized for COVID-19 and 902,088 controls with European genetic ancestry from COVID-19 Host Genetics Initiative. We found that five single nucleotide polymorphisms (SNPs) within TMPRSS2 and near MX1 gene show suggestive associations (P[≤]1x10-5) with severe COVID-19. All five SNPs replicated the association in two independent cohorts of Asian subjects while two and one out of the 5 SNPs replicated in African and Italian populations, respectively (P[≤]0.05). The minor alleles of these five SNPs correlated with a reduced risk of developing severe COVID-19 and increased level of MX1 expression in blood. Our findings provide further evidence that host genetic factors can contribute to determine the different clinical presentations of COVID-19 and that MX1, an antiviral effector of type I and III interferon pathway, may be a potential therapeutic target.
- organism: human
- assay: GWAS summary statistics
- research focus: GWAS / association mapping
- approach: statistical model
- Citations
- 76
- FWCI
- 10.19
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Initial Whole Genome Sequencing and Analysis of the Host Genetic Contribution to COVID-19 Severity and Susceptibility
Fang Wang, Shujia Huang, … Lei Liu·Cell DiscoveryPeer-reviewed·Nov 10, 2020
- COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types.
B. J. Schmiedel, V. Chandra, … P. Vijayanand·bioRxiv·Dec 1, 2020
- Analysis of Genetic Host Response Risk Factors in Severe COVID-19 Patients
Krystyna Taylor, Sayoni Das, … Steve Gardner·medRxiv·Jun 17, 2020
- Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations.
Roberta Russo, Immacolata Andolfo, … Mario Capasso·bioRxiv·Apr 23, 2020
- Insights into genetic factors contributing to variability in SARS-CoV-2 susceptibility and COVID-19 disease severity
Matteo D’Antonio, Jennifer Nguyen, … Rasoul Aliannejad·Cell ReportsPeer-reviewed·Nov 1, 2021
- A second update on mapping the human genetic architecture of COVID-19
The COVID-19 Host Genetics Initiative, Andrea Ganna·medRxiv·Dec 24, 2022